Onco-Innovations signs LOI with Ifowonco for option, global license to LAG-3 small-molecule program

Reuters2026/08/19 22:40

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Onco-Innovations signed a non-binding LOI with Ifowonco to negotiate an exclusive option and worldwide license for a LAG-3 small-molecule inhibitor program.
Deal targets an oral LAG-3 immune checkpoint inhibitor platform, positioned as an alternative to intravenous monoclonal-antibody LAG-3 therapies.
Parties plan to evaluate combinations with ONC010, aiming to pair DNA damage response inhibition with LAG-3 blockade across solid tumors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Onco-Innovations Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608191840ACCESSWRNAPR_____1209568) on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Onco-Innovations signs LOI with Ifowonco for option, global license to LAG-3 small-molecule program

You may also like

Crypto prices